Grifols (GRFS) Inventory Average (2009 - 2025)
Grifols' (GRFS) quarterly Inventory Average came in at $3.8 billion in Q4 2025, up 108.15% YoY from $1.8 billion in Q4 2024, and up 108.15% on a QoQ basis from $1.8 billion in Q4 2024.
Grifols (GRFS) Inventory Average (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 16 years of Inventory Average data on file, last reported at $3.8 billion in Q4 2025.
- Quarterly Inventory Average rose 108.15% year-over-year to $3.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 billion (up 108.15% YoY) and the FY2025 annual result came in at $3.8 billion, up 108.15% from the prior year.
- Inventory Average improved to $3.8 billion in Q4 2025, from $1.8 billion in the prior quarter.
- In the past five years, Inventory Average ranged from a high of $3.8 billion in Q4 2025 to a low of -$163.9 million in Q4 2021.
- A 5-year average of $1.0 billion and a median of -$110.1 million in 2023 frame the typical range for Inventory Average.
- Annual changes were most pronounced in 2021 — Inventory Average tumbled 115.08% — and 2024, when it surged 1767.5%.
- Tracing GRFS's Inventory Average over 5 years: stood at -$163.9 million in 2021, then gained by 18.14% to -$134.1 million in 2022, then advanced by 17.95% to -$110.1 million in 2023, then surged by 1767.5% to $1.8 billion in 2024, then jumped by 108.15% to $3.8 billion in 2025.
- The last three Inventory Average figures came in at $3.8 billion (Q4 2025), $1.8 billion (Q4 2024), and -$110.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | 14.86 Bn |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | 5.09 Bn |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | 6.34 Bn |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 6.75 Bn |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | 6.20 Bn |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | 1.93 Bn |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | 10.31 Bn |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | 8.36 Bn |
| 10 | Grifols | 5.51 Bn | 4.51 Bn | - | 3.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.82 Bn |
| Dec 31, 2024 | 1.84 Bn |
| Dec 31, 2023 | -110.07 Mn |
| Dec 31, 2022 | -134.15 Mn |
| Dec 31, 2021 | -163.88 Mn |
| Dec 31, 2020 | 1.09 Bn |
| Sep 30, 2020 | 2.52 Bn |
| Mar 31, 2020 | 2.65 Bn |
| Dec 31, 2019 | 2.59 Bn |
| Sep 30, 2019 | 2.50 Bn |
| Mar 31, 2019 | 2.31 Bn |
| Dec 31, 2018 | 2.20 Bn |
| Sep 30, 2018 | 2.16 Bn |
| Jun 30, 2018 | 2.11 Bn |
| Mar 31, 2018 | 1.99 Bn |
| Dec 31, 2017 | 1.84 Bn |
| Dec 31, 2016 | 1.75 Bn |
| Sep 30, 2016 | 1.73 Bn |
| Dec 31, 2015 | 1.54 Bn |
| Mar 31, 2015 | 1.52 Bn |